Loading company…
ID 434172977 · FY 2019–2023 · 5 years
1.2 კომპანიის ძირითად საქმიანობას წარმოადგენს: - საბითუმო და საცალო ვაჭრობა ფარმაცევტული საქონლით.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | CAGR |
|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 118 | 169 | -301 | 1,104 | 1,122 | +75.7% |
| Net Cash used in Investing Activities | 0 | 0 | 0 | -968 | 0 | |
| Free Cash Flow (OCF − Capex proxy) | 118 | 169 | -301 | 136 | 1,122 | +75.7% |
| Net Cash from Financing Activities | 0 | 0 | 197 | -132 | -1,184 | nmf |
| Net Change in Cash (before FX) | 118 | 169 | -104 | 4 | -62 | nmf |
| Effect of FX on Cash | -17 | -16 | -11 | -39 | -20 | +3.1% |
| Net Change in Cash (incl. FX) | 100 | 153 | -116 | -35 | -82 | nmf |
| Cash at Beginning of Year | 5 | 105 | 258 | 142 | 107 | +117.5% |
| Cash at End of Year | 105 | 258 | 142 | 107 | 25 | -30.2% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).